Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions: DRUG: RAD140
Sponsor: Stemline Therapeutics, Inc.